Table 2.
Coagulation parameters of patient 1 in the setting of acalabrutinib-related subungual hematoma.
| Parameters | Reference range | Initial | Follow-up (6 weeks after holding acalabrutinib) |
|---|---|---|---|
| PT | 9.7–13.0 sec | 12.5 | 12.5 |
| APTT | 23.0–32.4 sec | 31.6 | 31.1 |
| Platelet count | 150–400 k/uL | 171 | 122 |
| Factor VIII | 50–173% | 135 | 106 |
| VWF: Ag | 50–173% | 162 | 126 |
| VWF: RCo | 42–146% | 76 | 76 |
| VWF: CB | 41–161% | 91 | 72 |
| FVIII/VWF ratio | >0.4 | 0.8 | 0.8 |
| RCo/VWF ratio | >0.4 | 0.5 | 0.6 |
| CB/VWF ratio | >0.5 | 0.6 | 0.6 |
| Multimeric analysis | |||
| Low MW multimers | 8.9–23.1% | 41.1 | 34.7 |
| Intermediate MW multimers | 21.6–38.9% | 34.6 | 32.5 |
| High MW multimers | 39.9–68.3% | 24.3 | 32.8 |
| IgM κ monoclonal protein | 0 g/dL | 0.41 | 0.33 |
| IgM | 40–230 mg/dL | 638 | 505 |
vWF: von Willebrand factor, Ag: antigen, RCo: ristocetin cofactor, CB: collagen binding, and MW: molecular weight.